SOURCE: Novo Nordisk A/S

August 07, 2009 11:16 ET

Novo Nordisk A/S - Transaction in Own Shares

BAGSVÆRD, DENMARK--(Marketwire - August 7, 2009) - Novo Nordisk A/S - Share repurchase programme

On 29 January 2009, Novo Nordisk A/S, as part of the overall share repurchase programme for the period 2006-2009, initiated a share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

Under the programme Novo Nordisk A/S has repurchased B shares for an amount of DKK 3.0 billion in the period from 29 January 2009 to 5 August 2009. Consequently, the programme has been concluded on 5 August 2009.

Since the announcement as of 3 August 2009, the following transactions have been made under the programme:

              Number of  Average          Transaction value,
                shares   purchase                     DKK
                          price
Accumulated,
last          10,439,882                      2,928,714,334
announcement
3 August 2009     77,400 306.9000                23,754,060
4 August 2009     77,900 304.9700                23,757,163
5 August 2009     75,000 313.6500                23,523,750
Accumulated
under the     10,670,182                      2,999,749,307
programme

Transactions related to Novo Nordisk's incentive programmes have resulted in a net sale by Novo Nordisk of 63,600 B shares in the period from 3 August 2009 to 6 August 2009. The shares in these transactions were not part of the Safe Harbour repurchase programme. With the transactions stated above, Novo Nordisk owns a total of 21,398,641 treasury shares, corresponding to 3.5% of the share capital. The total amount of shares in the company is 620,000,000 including treasury shares.

Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs more than 27,900 employees in 81 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit novonordisk.com.

Further information:

Media:                 Investors:

Outside North America: Outside North America:
Elin K Hansen          Mads Veggerby Lausten
Tel: (+45) 4442 3450   Tel: (+45) 4443 7919
ekh@novonordisk.com    mlau@novonordisk.com

                       Kasper Roseeuw Poulsen
                       Tel: (+45) 4442 4471
                       krop@novonordisk.com

In North America:      In North America:
Sean Clements          Hans Rommer
Tel: (+1) 609 514 8316 Tel: (+1) 609 919 7937
secl@novonordisk.com   hrmm@novonordisk.com

Company Announcement no 47 / 2009

This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.

Copyright © Hugin AS 2009. All rights reserved.

Contact Information